| Collins, Graham |
| Recruiting | 3 | 1042 | Europe, US, RoW | Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim | University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group | Hodgkin Lymphoma | 09/30 | 09/32 | | |
AVENuE, NCT03617666: Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study |
|
|
| Active, not recruiting | 2 | 49 | Europe, RoW | Avelumab, Bavencio | University College, London, Pfizer | Hodgkin Lymphoma | 07/22 | 05/25 | | |
| Active, not recruiting | 2 | 78 | Europe | Nivolumab, Opdivo® | University College, London, Bristol-Myers Squibb | Hodgkin Lymphoma | 03/23 | 02/26 | | |
| Active, not recruiting | 2 | 82 | Europe, US, RoW | brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone | Seagen Inc. | Peripheral T-cell Lymphoma | 05/24 | 12/25 | | |
P+R-ICE, NCT05221645: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Active, not recruiting | 2 | 65 | Europe | Pembrolizumab, KEYTRUDA, Rituximab, MabThera, Ifosfamide, Carboplatin, Etoposide | University of Southampton, Merck Sharp & Dohme LLC | Diffuse Large B Cell Lymphoma | 05/26 | 12/26 | | |
RATiFY, NCT05627115: Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma |
|
|
| Not yet recruiting | 2 | 80 | NA | Tislelizumab, AVD, Radiotherapy, Response-adapted incorporation of tislelizumab | University College, London, BeiGene | Hodgkin Lymphoma | 10/28 | 10/28 | | |
NCT05463263: A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas |
|
|
| Recruiting | 1/2 | 180 | Europe, US | STP938 | Step Pharma, SAS | Lymphoma, B-Cell, Lymphoma, T-Cell | 12/25 | 12/25 | | |
| Betts, Tim R |
SMART-ALERT, NCT05207150: Continuous Rhythm Monitoring With Implantable Cardiac Monitors And Wearable Devices With Real-time Smartphone Alerts During AF Episodes |
|
|
| Completed | N/A | 50 | Europe | LINQII/Apple Watch Series 6, LINQII/SkyLabs CART-I ring | Oxford University Hospitals NHS Trust | Atrial Fibrillation | 08/22 | 06/23 | | |
| Completed | N/A | 500 | Europe | Group A, Group B | Oxford University Hospitals NHS Trust, University Hospital Birmingham, University Hospital Southampton NHS Foundation Trust | Cardiac Arrhythmia, Atrial Fibrillation | 04/23 | 04/23 | | |
| Terminated | N/A | 6 | Europe | Confirm Rx (Implantable Cardiac Monitor), Reveal LINQ (Implantable Cardiac Monitor) | Oxford University Hospitals NHS Trust | Atrial Fibrillation | 11/23 | 11/23 | | |
| Active, not recruiting | N/A | 1686 | Europe, Canada, Japan, US, RoW | SyncAV programmed ON, Fixed AV delay | Abbott Medical Devices | Congestive Heart Failure | 06/25 | 12/25 | | |
| Active, not recruiting | N/A | 965 | Europe, US | ommitence of defibrillation testing | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Boston Scientific Corporation | Ventricular Arrythmia | 10/24 | 10/24 | | |
| Recruiting | N/A | 330 | Europe | Pre-implantation planning, ECGI mapping, Post-implantation assessment | EP Solutions SA | Heart Failure With Reduced Ejection Fraction | 09/25 | 06/26 | | |
| Withdrawn | N/A | 80 | Europe | Intrachamber ultrasound, Statistical shape analysis | Oxford University Hospitals NHS Trust | Atrial Fibrillation, Atrial Fibrillation, Persistent | 09/26 | 09/26 | | |
DISCOVER, NCT03893331: AcQMap® Global Registry of Procedural and Long-term Clinical Outcomes (AcQMap Registry) |
|
|
| Terminated | N/A | 479 | Europe | AcQMap System | Acutus Medical | Ablation of Arrhythmia's | 11/23 | 11/23 | | |
| Chamberlin, Paul |
IMPROVE-DiCE, NCT04826159: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2) |
|
|
| Recruiting | 2 | 50 | Europe | IMB-1018972 | Imbria Pharmaceuticals, Inc., University of Oxford | Type 2 Diabetes, Diabetic Cardiomyopathies, HFpEF - Heart Failure With Preserved Ejection Fraction | 03/24 | 03/24 | | |
|
|
NCT04306237: A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina |
|
|
| Suspended | 2 | 640 | US | IMB-1018972, Placebo oral tablet | Imbria Pharmaceuticals, Inc. | Refractory Angina | 02/25 | 04/25 | | |
| Rinaldi, Simon |
NCT03943589: A Study of Imlifidase in Patients With Guillain-Barré Syndrome |
|
|
| Completed | 2 | 30 | Europe | Imlifidase, Hansa Medical-Immunoglobulin G degrading enzyme of Streptococcus pyogenes (HMED-IdeS), IdeS, IgG endopeptidase | Hansa Biopharma AB | Guillain-Barré Syndrome (GBS) | 02/24 | 02/24 | | |
ARDA+, NCT05405361 / 2021-004998-32: A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Multifocal Motor Neuropathy |
|
|
| Active, not recruiting | 2 | 51 | Europe, Canada, US | ARGX-117, Placebo | argenx, argenx BV | Multifocal Motor Neuropathy (MMN) | 09/26 | 09/26 | | |
| Recruiting | N/A | 150 | Europe, Canada, Japan, US, RoW | | argenx | Multifocal Motor Neuropathy | 11/25 | 11/25 | | |
| Collins, Angela |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia |
|
|
| Recruiting | 2/3 | 148 | Europe | Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib | University College, London, Janssen-Cilag Ltd. | Waldenstrom Macroglobulinemia | 03/30 | 03/30 | | |
| Completed | 2 | 17 | Europe | Pembrolizumab, Rituximab | University College, London, Merck Sharp & Dohme LLC | Waldenstrom Macroglobulinemia | 09/21 | 02/24 | | |
| Uberoi, Raman |
CALCIO, NCT06149650: Chronic Limb-Threatening Ischemia Treated with Intravascular Lithotripsy Observational Study |
|
|
| Recruiting | N/A | 400 | Europe | Shockwave Medical IVL System | Cardiovascular and Interventional Radiological Society of Europe, Shockwave Medical, Inc. | Chronic Limb-Threatening Ischemia | 07/28 | 12/28 | | |
| Recruiting | N/A | 1000 | Europe, US | Thoracic, Abdominal, Custom Device, Illiac Artery | Vascutek Ltd., Bolton Medical | Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery | 11/29 | 11/30 | | |
| Lamb, Alastair |
IP2-ATLANTA, NCT03763253: Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms |
|
|
| Recruiting | 2 | 399 | Europe | Standard of Care, Minimally Invasive Ablative Therapy (MIAT), Metastatic Directed Therapy (MDT), Radical Therapy (Prostatectomy or Radiotherapy) | Imperial College London, Wellcome Trust | Prostate Cancer, Metastatic Prostate Cancer | 08/26 | 01/27 | | |
| Recruiting | N/A | 1042 | Europe | Prostate biopsy | University of Oxford, National Institute for Health Research, United Kingdom | Prostate Cancer | 12/22 | 10/23 | | |
| Koritnik, Blaž |
| Active, not recruiting | 3 | 390 | Europe, RoW | Dolutegravir, Abacavir and Lamivudine, Triumeq, Placebo | Macquarie University, Australia, King's College London, Stichting TRICALS Foundation | Amyotrophic Lateral Sclerosis | 08/26 | 08/26 | | |
| Recruiting | N/A | 60 | Europe | Iowa Oral Performance Instrument (IOPI), Mann Assessment of Swallowing Ability (MASA), Fiberoptic Endoscopic Evaluation of Swallowing, Respiratory function measurements | University Rehabilitation Institute, Republic of Slovenia, University Medical Centre Ljubljana | Amyotrophic Lateral Sclerosis | 03/26 | 03/26 | | |
| Talks, Katherine |
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial |
|
|
| Recruiting | 3 | 150 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor | 11/28 | 11/28 | | |
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia A, Hemophilia B | 03/26 | 06/26 | | |
| Recruiting | N/A | 200 | Europe, Canada, US, RoW | No Intervention | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia A, Hemophilia B | 11/24 | 11/24 | | |
| Obaji, Samya |
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial |
|
|
| Recruiting | 3 | 150 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor | 11/28 | 11/28 | | |
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia A, Hemophilia B | 03/26 | 06/26 | | |
| Recruiting | N/A | 200 | Europe, Canada, US, RoW | No Intervention | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia A, Hemophilia B | 11/24 | 11/24 | | |
| Murali, Kesavan |
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia |
|
|
| Recruiting | 2/3 | 148 | Europe | Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib | University College, London, Janssen-Cilag Ltd. | Waldenstrom Macroglobulinemia | 03/30 | 03/30 | | |
| Pirkl, Martin |
IP2-ATLANTA, NCT03763253: Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms |
|
|
| Recruiting | 2 | 399 | Europe | Standard of Care, Minimally Invasive Ablative Therapy (MIAT), Metastatic Directed Therapy (MDT), Radical Therapy (Prostatectomy or Radiotherapy) | Imperial College London, Wellcome Trust | Prostate Cancer, Metastatic Prostate Cancer | 08/26 | 01/27 | | |
| Shapiro, Susan |
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial |
|
|
| Recruiting | 3 | 150 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor | 11/28 | 11/28 | | |
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia A, Hemophilia B | 03/26 | 06/26 | | |
| Not yet recruiting | N/A | 2500 | Europe | Venepuncture, Collection of relevant information | Microvisk Technologies Ltd | Pulmonary Embolism (Diagnosis), Deep Vein Thrombosis, Atrial Fibrillation (AF) | 10/29 | 11/29 | | |
